What is Noetik?
Noetik is at the forefront of AI-driven biotechnology, specializing in the creation of advanced cancer treatments. The company harnesses the power of self-supervised machine learning algorithms combined with high-throughput spatial data analysis to identify and develop novel therapeutic candidates. By focusing on these cutting-edge technologies, Noetik aims to revolutionize the oncology landscape and provide more effective treatment options for patients. The company's strategic positioning within the rapidly evolving biotech sector, coupled with its deep tech focus, suggests a strong potential for disruptive innovation.
How much funding has Noetik raised?
Noetik has raised a total of $54M across 2 funding rounds:
Angel/Seed
$14M
Series A
$40M
Angel/Seed (2023): $14M with participation from Intermountain Ventures, DCVC Management, 11.2 Capital, Zetta Venture Partners, EPIC Ventures, North South Ventures, and Catalio Capital Management
Series A (2024): $40M led by Wittington Ventures, Polaris Partners, and Khosla Ventures
Key Investors in Noetik
Intermountain Ventures
Intermountain Ventures is a strategic investment vehicle of Intermountain Healthcare, focused on high-return, high-growth opportunities aligned with Intermountain's mission to improve health outcomes.
DCVC Management
DCVC is a deep tech venture capital firm investing in entrepreneurs tackling major global challenges, with a focus on leveraging AI across sectors like biotechnology and energy.
Wittington Ventures
Wittington Investments Limited is a private Canadian family company with diverse investments, including significant holdings in retail and property.
What's next for Noetik?
With the recent influx of major strategic investment and a significant total funding amount of $54M, Noetik is poised for an accelerated growth phase. This substantial backing, particularly the recent $40M round, indicates a Series A or later stage of development, suggesting the company is moving beyond initial research and into scaling its operations and clinical development. The strategic capital infusion will likely be deployed to expand its research and development teams, advance its lead therapeutic candidates through preclinical and clinical trials, and potentially forge strategic partnerships within the pharmaceutical industry. Noetik's focus on AI and spatial data positions it to address complex challenges in cancer therapy, making it a company to watch in the biotech investment space.
See full Noetik company page
